Know Cancer

forgot password

A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-Cell Lymphoma

Phase 2
18 Years
65 Years
Open (Enrolling)
Peripheral T-Cell Lymphoma

Thank you

Trial Information

A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-Cell Lymphoma

This is a multicentric, open-label, non-randomized, non-competitive clinical study,
evaluating the efficacy and safety of V-ACVBP chemotherapy in previously untreated patients
aged from 18 to 65 years with peripheral T-lymphoma.

It is anticipated that 60 subjects will be enrolled over two years (from June 2005 to May

The duration of the treatment period is approximately 28 weeks and patients are followed
until death.

The total duration of the study is expected to be 5 years (from June 2005 to May 2010).

Inclusion Criteria:

- Previously untreated non-cutaneous peripheral T-cell lymphoma, including human T-cell
lymphotropic virus type 1 (HTLV-1) related T-cell lymphoma, and natural killer
(NK)-cell lymphoma.

- Ages 18 to 65 years.

- Life expectancy > 3 months.

- Written informed consent.

Exclusion Criteria:

- B-cell lymphoma or other subtype of T-cell lymphoma including anaplastic large cell
lymphoma AKL(+), lymphoblastic lymphoma and primary cutaneous T-cell lymphoma.

- Any previous therapy for lymphoma except for short-term corticosteroids before

- Inability to tolerate the ACVBP regimen according to investigator's judgement.

- Positive serology for HIV.

- Poor renal function (creatinin > 150 µmol/l within 14 days before enrollment), poor
liver function (total bilirubin > 30 µmol/l, transaminases > 2.5 upper normal limit
[UNL] within 14 days before enrollment), unless these abnormalities are related to
the lymphoma.

- Poor bone marrow reserve as defined by neutrophils < 1.5 G/l or platelets < 100 G/l
within 14 days before enrollment, unless these abnormalities are related to the

- Patient with >= grade 2 peripheral neuropathy non-related to lymphoma.

- Any central nervous system (CNS) disease.

- CNS or meningeal involvement by the lymphoma.

- Any serious active disease or comorbidity according to the investigator's decision.

- Any history of cancer during the last 5 years with the exception of non-melanoma skin
tumours or stage 0 (in situ) cervical carcinoma.

- Known hypersensitivity to bortezomib, boron or mannitol.

- Contraindication to any cytotoxic drug contained in chemotherapy regimen.

- Pregnant or lactating women or women of childbearing potential not willing to use an
adequate method of birth control (i.e. hormonal contraceptive, intra-uterine device,
diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of

- Men not agreeing to take adequate contraceptive precautions during the study.

- Treatment with investigational drug within 30 days before planned first cycle of
chemotherapy and during the study.

- Adult patient under tutelage.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy measured by event-free survival (EFS), events being defined as disease progression, institution of a new treatment for the lymphoma, relapse after complete response (CR), or death from any cause

Principal Investigator

Bertrand Coiffier, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Hospices Civils de Lyon, Lyon, France


France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:




Start Date:

November 2005

Completion Date:

November 2008

Related Keywords:

  • Peripheral T-cell Lymphoma
  • peripheral T-cell lymphomas
  • bortezomib
  • ACVBP regimen
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Peripheral